AbbVie, a global biopharmaceutical giant, has finalized a significant strategic collaboration with Haisco Pharmaceutical Group, a prominent Chinese biopharmaceutical company.…
Read More
Sidewinder Therapeutics Secures $137 Million in Series B Financing to Advance Bispecific Antibody-Drug Conjugate Pipeline
Sidewinder Therapeutics has announced the successful closure of a substantial $137 million Series B financing round, a significant development signaling…
Read More
Gilead Acquires Antibody-Drug Conjugate Pioneer Tubulis for Up to $5 Billion, Bolstering Oncology Pipeline
Sixteen months after forging a strategic collaboration, Gilead Sciences has announced its definitive agreement to acquire German biotechnology firm Tubulis,…
Read More
Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion, Bolstering Neuroscience Pipeline
Eli Lilly and Company announced a significant move to acquire Centessa Pharmaceuticals, a UK-based biopharmaceutical company specializing in neuroscience, in…
Read More
Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Bolster Psychiatric and Neurological Pipeline
TOKYO, JAPAN & BOSTON, USA – March 30, 2026 – Otsuka Pharmaceutical Co., Ltd. announced today that its subsidiary, Otsuka…
Read More
Novartis to Acquire Excellergy for Up to $2 Billion to Bolster Next-Generation Anti-IgE Allergy Pipeline
Novartis has entered into a definitive agreement to acquire Excellergy, a privately held biotechnology company specializing in the development of…
Read More
MSD Acquires Terns Pharmaceuticals for $6.7 Billion in Strategic Move to Bolster Oncology Pipeline Ahead of Keytruda Patent Expiry
In a significant development poised to reshape the competitive landscape of cancer therapeutics, global pharmaceutical giant MSD (known as Merck…
Read More
Earendil Labs Secures $787 Million to Accelerate AI-Driven Drug Discovery and Expand Robust Pipeline
Earendil Labs, a burgeoning biotechnology firm at the forefront of artificial intelligence (AI)-powered drug discovery, has announced a significant financial…
Read More
Congruence secures $39.5m to advance small molecule correctors pipeline
Congruence Therapeutics, a pioneering biotechnology company focused on developing novel small molecule correctors, has successfully closed a significant $39.5 million…
Read More
Excalipoint Therapeutics Launches with $68.7 Million Seed Funding to Advance Novel T-Cell Engager Pipeline
Chinese biotech startup Excalipoint Therapeutics has officially launched with a substantial $68.7 million in seed funding, positioning itself to accelerate…
Read More
